학술논문
Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic.
Document Type
Academic Journal
Author
Ariza-Vioque E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Ello F; Programme ANRS Coopération Côte d'Ivoire (PAC-CI), Abidjan, Ivory Coast.; Andriamamonjisoa H; Institut Pasteur de Madagascar, Antananarivo, Madagascar.; Machault V; INSERM U1219, Bordeaux Population Health (BPH), Université de Bordeaux, Bordeaux, France.; González-Martín J; Servei de Microbiologia, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Barcelona, Spain.; Institut de Salut Global (ISGlobal), Barcelona, Spain.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.; Calvo-Cortés MC; Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS), Maladies Infectieuses Émergentes, Paris, France.; Eholié S; Centre Hospitalier Universitaire (CHU) Treichville, Abidjan, Ivory Coast.; Tchabert GA; Programme ANRS Coopération Côte d'Ivoire (PAC-CI), Abidjan, Ivory Coast.; Ouassa T; Centre de Diagnostic et de Research sur le SIDA et les autres maladies infectieuses (CeDReS), Abidjan, Ivory Coast.; Raberahona M; Centre d'Infectiologie Charles Mérieux (CICM), Antananarivo, Madagascar.; Université d'Antananarivo, Antananarivo, Madagascar.; Centre Hospitalier Universitaire (CHU) Joseph Raseta Befalatanana, Antananarivo, Madagascar.; Rakotoarivelo R; Université de Fianarantsoa, Fianarantsoa, Madagascar.; Centre Hospitalier Universitaire (CHU) Tambohobe, Fianarantsoa, Madagascar.; Razafindrakoto H; Centre d'Infectiologie Charles Mérieux (CICM), Antananarivo, Madagascar.; Rahajamanana L; Centre d'Infectiologie Charles Mérieux (CICM), Antananarivo, Madagascar.; Wilkinson RJ; Wellcome Centre for Infectious Diseases Research in Africa, Cape Town, Republic of South Africa.; Francis Crick Institute, London, UK.; Department Infectious Diseases, Imperial College London, London, UK.; Davis A; Wellcome Centre for Infectious Diseases Research in Africa, Cape Town, Republic of South Africa.; Maxebengula M; Wellcome Centre for Infectious Diseases Research in Africa, Cape Town, Republic of South Africa.; Abrahams F; Wellcome Centre for Infectious Diseases Research in Africa, Cape Town, Republic of South Africa.; Muzoora C; Médecins Sans Frontières (MSF) Epicentre, Mbarara, Uganda.; Mbarara University of Science and Technology (MUST), Mbarara, Uganda.; Nakigozi N; Médecins Sans Frontières (MSF) Epicentre, Mbarara, Uganda.; Nyehangane D; Médecins Sans Frontières (MSF) Epicentre, Mbarara, Uganda.; Nanjebe D; Médecins Sans Frontières (MSF) Epicentre, Mbarara, Uganda.; Mbega H; Médecins Sans Frontières (MSF) Epicentre, Mbarara, Uganda.; Kaitano R; Médecins Sans Frontières (MSF) Epicentre, Mbarara, Uganda.; Bonnet M; Université de Montpellier, Montpellier, France.; Recherches Translationnelles sur le VIH et les Maladies Infectieuses (TransVIHMI), Institut de Recherche pour le Développement (IRD), INSERM, Paris, France.; Debeaudrap P; Recherches Translationnelles sur le VIH et les Maladies Infectieuses (TransVIHMI), Institut de Recherche pour le Développement (IRD), INSERM, Paris, France.; Miró JM; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.; HIV Unit, Infectious Diseases Service, Hospital Clínic de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.; Anglaret X; Programme ANRS Coopération Côte d'Ivoire (PAC-CI), Abidjan, Ivory Coast.; INSERM U1219, Bordeaux Population Health (BPH), Université de Bordeaux, Bordeaux, France.; Rakotosamimanana N; Institut Pasteur de Madagascar, Antananarivo, Madagascar.; Calmy A; Université de Genève (UNIGE), Geneva, Switzerland.; Bonnet F; INSERM U1219, Bordeaux Population Health (BPH), Université de Bordeaux, Bordeaux, France.; Service de Médecine Interne et Maladies Infectieuses, Saint-André Hospital, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France.; Ambrosioni J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. jambrosioni@intramed.net.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain. jambrosioni@intramed.net.; HIV Unit, Infectious Diseases Service, Hospital Clínic de Barcelona, Barcelona, Spain. jambrosioni@intramed.net.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. jambrosioni@intramed.net.
Source
Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2193-8229
Abstract
Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa.
(© 2022. The Author(s).)
(© 2022. The Author(s).)